These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23190454)

  • 21. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
    Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Jit M; Henderson B; Stevens M; Seymour RM
    Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
    Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K
    J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?
    Marotte H; Cimaz R
    Expert Opin Biol Ther; 2014 May; 14(5):569-72. PubMed ID: 24611432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor (TNF)-soluble high-affinity receptor complex as a TNF antagonist.
    McKenna SD; Feger G; Kelton C; Yang M; Ardissone V; Cirillo R; Vitte PA; Jiang X; Campbell RK
    J Pharmacol Exp Ther; 2007 Aug; 322(2):822-8. PubMed ID: 17495128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.
    Im SJ; Yang SI; Yang SH; Choi DH; Choi SY; Kim HS; Jang DS; Jin KS; Chung YK; Kim SH; Paik SH; Park YC; Chung MK; Kim YB; Han KH; Choi KY; Sung YC
    PLoS One; 2011; 6(9):e24574. PubMed ID: 21957455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis.
    Simelyte E; Criado G; Essex D; Uger RA; Feldmann M; Williams RO
    Arthritis Rheum; 2008 Apr; 58(4):1038-43. PubMed ID: 18383359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
    Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
    Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
    N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality.
    Lesslauer W; Tabuchi H; Gentz R; Brockhaus M; Schlaeger EJ; Grau G; Piguet PF; Pointaire P; Vassalli P; Loetscher H
    Eur J Immunol; 1991 Nov; 21(11):2883-6. PubMed ID: 1657617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye.
    Ji YW; Byun YJ; Choi W; Jeong E; Kim JS; Noh H; Kim ES; Song YJ; Park SK; Lee HK
    Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7557-66. PubMed ID: 24052636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
    Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C
    J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.
    Murray KM; Dahl SL
    Ann Pharmacother; 1997 Nov; 31(11):1335-8. PubMed ID: 9391689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
    Coppieters K; Dreier T; Silence K; de Haard H; Lauwereys M; Casteels P; Beirnaert E; Jonckheere H; Van de Wiele C; Staelens L; Hostens J; Revets H; Remaut E; Elewaut D; Rottiers P
    Arthritis Rheum; 2006 Jun; 54(6):1856-66. PubMed ID: 16736523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
    Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
    Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept Immunex.
    Yung RL
    Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.